AITOPAI热报
Industry

中国用 AI 加速新药设计，西方药企数十亿美元订单涌入

Rest of World@restofworld
Post
View the post
Why we picked it

Rest of World 报道了中国 AI 制药如何快速设计新药分子，还拿到西方药巨头的数十亿美元合作，连争议点也一起讲了。

中国团队正在用 AI 设计新的药物候选分子，把研发周期大幅压缩，速度创下纪录。这种做法吸引西方大型制药公司签下累计数十亿美元的合作交易。

Image · Rest of World
Body

Rest of World 的报道指出，这些交易同时引发了 awe 和 suspicion 两种反应，外界对技术来源和安全性存有疑虑。

Original · Rest of World

China is using AI to design new drug candidates in record time, attracting billions in deals from Western pharma giants.

Why has this been met with both awe and suspicion? https://t.co/n9UD3E8QFt

Industry Coordinates & Source Verification

This report is categorized under AITOP's "Industry" desk, focusing on China's AI industry and domestic foundation model ecosystem. Within our cross-regional analytical framework, it directly maps to US-China foundation model benchmarks and commercialization comparison and AI regulation, compliance frameworks, and sovereign compute policy. Key entities and technical topics under continuous tracking include AI制药, 药物研发, Rest of World, AI安全.

Source attribution: curated from Rest of World (@restofworld).

#AI制药#药物研发#Rest of World#AI安全

Keep reading

Recent stories with the same tag or section
ProductsBuilders13:42
Chinese contentPhaSER Biomedical获盖茨基金会270万美元资助，推进8HUM模型与HERALD AI

药企做临床前毒性筛选的老办法是拿小鼠凑合，人代谢和小鼠代谢差太多，漏掉的毒性到人体试验才暴露。这家苏格兰公司用带人类代谢酶基因的转基因小鼠加HERALD AI来补这个坑，盖茨基金会给了270万美元。做药物研发或关注AI制药的人可以看看。

#PhaSER Biomedical#HERALD AI#8HUM#药物研发
HIT Consultant@Jasmine PennicSource
ModelsBuilders72°07:30
Chinese content谷歌 DeepMind 发布 AlphaGenome 2：深入单细胞层面预测基因变异影响

DeepMind 把基因组预测从组织级别推进到了单细胞级别，致病变异识别率从 16% 提到 30%，还首次支持 DNA 甲基化预测。做遗传学、药物研究的科研人员可以直接用 API 免费跑，不用自己微调模型就能分析新细胞类型。

#AlphaGenome 2#Google DeepMind#基因组学#单细胞分析
IT之家Source
IndustryBuildersMulti-source00:52
Chinese contentDario Amodei 预测癌症、阿尔茨海默病等疾病十年内或被攻克

Anthropic 的 CEO 放话十年内攻克癌症和阿尔茨海默病，正好卡在 IPO 节点前，动机值得琢磨。AI 制药确实在提速，但十年说法业内争议不小。关心 AI 医疗落地和 Anthropic 动向的人可以看看各方怎么看。

#Anthropic#Dario Amodei#AI制药#生物医药
Event
kimmonismus@kimmonismusSource
ProductsBuildersSelected23:27
Google DeepMind releases AlphaGenome 2 for cell-specific disease research

Cell-specific variant interpretation is a bottleneck in translating genome sequencing into clinical insight, and AlphaGenome 2 targets exactly that gap. Genomics labs, computational biologists, and biotech teams evaluating disease-causing mutations can use it to prioritise variants by affected tissue. Compared with AlphaFold, which resolved protein structure, this model moves DeepMind's tooling upstream into gene regulation, a space where competitors like Enformer and Evotec partnerships have been active.

#AlphaGenome#Google DeepMind#genomics#variant interpretation
Official accountGoogle DeepMind@GoogleDeepMindSource